Literature DB >> 12950039

Exhaled nitric oxide corresponds with office evaluation of asthma control.

Isabelle Meyts1, Marijke Proesmans, Kris De Boeck.   

Abstract

Exhaled NO (ENO) has been studied as a noninvasive marker of airway inflammation, and has been shown to be elevated in asthma patients. The aim of this study was to investigate whether ENO measurements differ significantly between groups of asthmatic children with different disease control and to compare ENO measurements with the clinical assessment of asthma control. Seventy-three children between 5-18 years old with a diagnosis of asthma were recruited. ENO was measured online during a slow vital capacity maneuver. The mean of three plateau NO levels was used for analysis. Baseline and postbronchodilator spirometry were performed. The assessment of disease control was based on the frequency of use of beta2-agonists, occurrence of day- and nighttime asthma symptoms, and spirometry results. Twenty-one children (group 1) had good asthma control. In 31 patients (group 2), asthma control was acceptable. In 21 patients (group 3), asthma was insufficiently controlled. ENO levels were (median (quartiles)): group 1, 11 ppb (9-21); group 2, 15 ppb (11-26); and group 3, 28 ppb (19-33). Measurements were significantly different between all three groups (P = 0.009, Kruskal-Wallis), between groups 1 and 3 (P = 0.01, Mann-Whitney U test), and between groups 2 and 3 (P = 0.01, Mann-Whitney-U test). The same was true for reversibility testing. We found significantly different ENO levels between a group of pediatric asthma patients with insufficient and good/sufficient control, as defined by clinical assessment. These results suggest that ENO measurements may be useful for monitoring asthma patients. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12950039     DOI: 10.1002/ppul.10317

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  6 in total

1.  Associations of Fraction of Exhaled Nitric Oxide with Beta Agonist Use in Children with Asthma.

Authors:  Adam J Spanier; Robert S Kahn; Richard Hornung; Michelle Lierl; Bruce P Lanphear
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2011-03       Impact factor: 1.349

2.  Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial.

Authors:  Stanley J Szefler; Herman Mitchell; Christine A Sorkness; Peter J Gergen; George T O'Connor; Wayne J Morgan; Meyer Kattan; Jacqueline A Pongracic; Stephen J Teach; Gordon R Bloomberg; Peyton A Eggleston; Rebecca S Gruchalla; Carolyn M Kercsmar; Andrew H Liu; Jeremy J Wildfire; Matthew D Curry; William W Busse
Journal:  Lancet       Date:  2008-09-20       Impact factor: 79.321

Review 3.  Outcomes in pediatric asthma.

Authors:  Michael S Blaiss; Brandon Hill
Journal:  Curr Allergy Asthma Rep       Date:  2005-11       Impact factor: 4.806

4.  Chemical-induced asthma and the role of clinical, toxicological, exposure and epidemiological research in regulatory and hazard characterization approaches.

Authors:  Melissa J Vincent; Jonathan A Bernstein; David Basketter; Judy S LaKind; G Scott Dotson; Andrew Maier
Journal:  Regul Toxicol Pharmacol       Date:  2017-09-01       Impact factor: 3.271

Review 5.  Exhaled nitric oxide: a test for diagnosis and control of asthma?

Authors:  Rohit Katial; Lora Stewart
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

Review 6.  2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.

Authors:  Michelle M Cloutier; Alan P Baptist; Kathryn V Blake; Edward G Brooks; Tyra Bryant-Stephens; Emily DiMango; Anne E Dixon; Kurtis S Elward; Tina Hartert; Jerry A Krishnan; Robert F Lemanske; Daniel R Ouellette; Wilson D Pace; Michael Schatz; Neil S Skolnik; James W Stout; Stephen J Teach; Craig A Umscheid; Colin G Walsh
Journal:  J Allergy Clin Immunol       Date:  2020-12       Impact factor: 10.793

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.